{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/","result":{"pageContext":{"chapter":{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids","depth":2,"htmlHeader":"<!-- begin field 3cc6beef-2a38-43d9-b00f-616fc44fd350 --><h2>Topical corticosteroids</h2><!-- end field 3cc6beef-2a38-43d9-b00f-616fc44fd350 -->","summary":"","htmlStringContent":"<!-- begin item 8a7f6ff2-1644-40af-9821-07d0e8469842 --><!-- end item 8a7f6ff2-1644-40af-9821-07d0e8469842 -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"519df620-cf15-593a-984f-7944dd78b85b","slug":"available-products","fullItemName":"Available products","depth":3,"htmlHeader":"<!-- begin field 5f4c2928-70a1-4e3b-b2e0-1b4a90717a38 --><h3>Which topical corticosteroids are available?</h3><!-- end field 5f4c2928-70a1-4e3b-b2e0-1b4a90717a38 -->","summary":"","htmlStringContent":"<!-- begin item 3cfe87ea-b7a7-4ef9-920b-48fbb74f07de --><!-- begin field 5fd2cf07-2ad9-4784-acf4-335f20d183b5 --><ul><li><strong>Topical corticosteroids are available in four potencies: mildly potent, moderately potent, potent, and very potent. </strong><ul><li>These include creams, ointments, lotion, gel, and/or scalp applications, available as non-proprietary and/or proprietary products.</li><li>Examples include:<ul><li>Mildly potent — hydrocortisone 0.1%, 0.5%, 1.0%, and 2.5% </li><li>Moderately potent — betamethasone valerate 0.025% (Betnovate-RD®) and clobetasone butyrate 0.05% (Eumovate®)</li><li>Potent — betamethasone valerate 0.1% (Betnovate®) and betamethasone dipropionate 0.05% (Diprosone®)</li><li>Very potent — clobetasol propionate 0.05% (Dermovate®) and diflucortolone valerate 0.3%(Nerisone Forte®)</li></ul></li><li>All are available on the NHS with an FP10 form. See the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"fc969474-0275-4e2a-90a3-a8f7014de163\">BNF</a>) for a complete list of all the topical corticosteroids available in the UK. </li></ul></li><li><strong>Note that:</strong><ul><li>Hydrocortisone 1% is available over-the-counter for the treatment of mild-to-moderate eczema not involving the face or genitals.</li><li>Very potent topical corticosteroids should usually only be prescribed by specialists.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>]</p><!-- end field 5fd2cf07-2ad9-4784-acf4-335f20d183b5 --><!-- end item 3cfe87ea-b7a7-4ef9-920b-48fbb74f07de -->","subChapters":[]},{"id":"1f67a96f-85da-5fef-9f47-d2437208cced","slug":"regimen-for-flares","fullItemName":"Regimen for flares","depth":3,"htmlHeader":"<!-- begin field e1b8ea21-248a-4c14-b2fa-e60e460c0889 --><h3>What regimen of topical corticosteroid should I prescribe for a flare?</h3><!-- end field e1b8ea21-248a-4c14-b2fa-e60e460c0889 -->","summary":"","htmlStringContent":"<!-- begin item 7442b421-8e17-4293-ad63-8df242c932b3 --><!-- begin field 9df757a2-97af-4b6d-817e-0c5b0b8543e7 --><ul><li><strong>For normal skin on the body (not the face, genitals, or axillae):</strong><ul><li>Prescribe a strength of topical corticosteroid to match the severity of the eczema, to be used once a day for 7–14 days:<ul><li><strong>For mild eczema</strong> — prescribe a <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/#available-products\">mildly potent</a> topical corticosteroid.</li><li><strong>For moderate eczema</strong> — prescribe a <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/#available-products\">moderately potent</a> corticosteroid.</li><li><strong>For severe eczema</strong> — prescribe a <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/#available-products\">potent</a> topical corticosteroid.</li></ul></li><li>The quantities of topical corticosteroid required to treat a flare of eczema for 1 week in an adult are listed below (about half of this is needed for a child) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>]:<ul><li>Face and neck: 15–30 g</li><li>Both hands: 15–30 g</li><li>Scalp: 15–30 g</li><li>Both arms: 30–60 g</li><li>Both legs: 100 g</li><li>Trunk: 100 g</li><li>Groin and genitalia: 15–30 g </li></ul></li><li>If the response to once daily application is inadequate, increase to twice daily.</li></ul></li><li><strong>For flares on the face, genitals, or axillae,</strong> consider prescribing a mild potency topical corticosteroid and increase to a moderate potency corticosteroid only if necessary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>].<ul><li>For moderate or severe flares on the face, genitals, or axillae, use a moderately potent corticosteroid for a maximum of 5 days. If this is insufficient, consider referral.</li></ul></li><li><strong>Prescribe an appropriate formulation for the person and their condition. </strong>Choosing<strong> </strong>a topical corticosteroid that is acceptable to the person is important as it will encourage compliance with treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">DTB, 2003</a>].<ul><li>Creams are preferred by most people, especially when used on visible areas, such as the face and hands.</li><li>Ointments provide the strongest emollient effect and may be more effective. However, they are greasy and so may be more suitable for use at night.</li><li>Other formulations (such as for scalp applications) are suitable for specific areas of skin.</li></ul></li><li>A Technology Appraisal published by the National Institute for Health and Care Excellence (NICE) recommends that 'where more than one alternative topical corticosteroid is considered clinically appropriate within a potency class, the drug with the lowest acquisition cost should be prescribed, taking into account pack size and frequency of application' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2004b</a>]. CKS recommends that cost should be taken into account, but not at the expense of preference.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>]</p><!-- end field 9df757a2-97af-4b6d-817e-0c5b0b8543e7 --><!-- end item 7442b421-8e17-4293-ad63-8df242c932b3 -->","subChapters":[]},{"id":"0870c210-b144-5353-945d-8082a3ca9d50","slug":"regimen-for-maintenance","fullItemName":"Regimen for maintenance","depth":3,"htmlHeader":"<!-- begin field a639faa1-27c8-4e8d-a559-ac43233b13eb --><h3>Regimen for maintenance</h3><!-- end field a639faa1-27c8-4e8d-a559-ac43233b13eb -->","summary":"","htmlStringContent":"<!-- begin item 7ac5a0cf-c108-46d2-a15e-dd5adc79e66b --><!-- begin field 51bcb987-b083-4b23-919c-7642bec381ed --><ul><li><strong>For the maintenance treatment of chronic eczema on the body (that is, skin other than the face, genitals, or axillae), </strong>consider one of the following treatment options: <ul><li><strong>Step down treatment</strong> — prescribe the lowest potency topical corticosteroid that controls the eczema — typically this will be a potency class down from what is used during a flare (for example prescribe a moderate potency corticosteroid for maintenance in people who have severe flares) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007b</a>].</li><li><strong>Intermittent treatment</strong> — consider one of the following two regimens:<ul><li>Weekend therapy — prescribe the usual topical corticosteroid, to be used on two consecutive days per week [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007b</a>].</li><li>Twice weekly therapy — prescribe the usual topical corticosteroid, to be used twice a week (for example every 3–4 days) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>].</li></ul></li><li>Treatment should be continued indefinitely, although an occasional drug holiday is advisable when step down treatment is being used.</li></ul></li><li><strong>For the maintenance treatment of chronic eczema on the face, genitals, or axillae, </strong>use a mild topical corticosteroid. If this is insufficient, consider referral.</li></ul><!-- end field 51bcb987-b083-4b23-919c-7642bec381ed --><!-- end item 7ac5a0cf-c108-46d2-a15e-dd5adc79e66b -->","subChapters":[]},{"id":"67dddb6d-fa89-5a79-b39f-26f126ed274d","slug":"prescribing-issues","fullItemName":"Prescribing issues","depth":3,"htmlHeader":"<!-- begin field 1c346cc8-d1e5-4161-845e-3697e195e681 --><h3>What do I need to know about prescribing topical corticosteroids?</h3><!-- end field 1c346cc8-d1e5-4161-845e-3697e195e681 -->","summary":"","htmlStringContent":"<!-- begin item 009484c5-7974-45d4-9f8d-ffda6f629d46 --><!-- begin field edce00d9-1cce-4c42-a2f1-c6739e81305d --><ul><li><strong>When used correctly, topical corticosteroids rarely cause serious adverse effects.</strong></li><li><strong>The likelihood of adverse effects is directly related to:</strong><ul><li>Duration of treatment — long-term treatment is likely to result in systemic absorption.</li><li>Area of the skin being treated — treating large areas of skin increases the risk of systemic absorption.</li><li>Condition of the skin — absorption is greatest in thin, inflamed skin.</li><li>Potency of the topical corticosteroid — the greater the potency, the greater the risk of systemic absorption.</li><li>Occlusion — use of topical corticosteroids under occlusion increases the risk of systemic absorption.</li><li>Age — children and older people are more susceptible to adverse effects because they have a thinner epidermis. Older people also have reduced dermal collagen (due to age and sun damage).</li></ul></li><li><strong>Local adverse effects are more common.</strong> They mostly occur on the face, in skin folds, and in areas that are treated over the long term. Local adverse effects include:<ul><li>Transient burning or stinging — this is common, especially in the first 2 days of application on untreated, inflamed skin. It does not usually require a change of treatment, as it improves as the skin responds to treatment.</li><li>Worsening and spreading of untreated infection.</li><li>Thinning of the skin — the skin improves after stopping treatment.</li><li>Permanent striae.</li><li>Allergic contact dermatitis — due to the corticosteroid or the excipients.</li><li>Acne vulgaris (or worsening of existing acne) or acne rosacea.</li><li>Mild depigmentation — usually reversible.</li><li>Excessive hair growth at the site of application (hypertrichosis).</li></ul></li><li><strong>Systemic adverse effects</strong> <strong>are rare,</strong> but may include:<ul><li>Adrenal suppression.</li><li>Cushing's syndrome.</li><li>Growth suppression in children.</li></ul></li><li><strong>For detailed prescribing information on topical corticosteroids, including contraindications and cautions and advice on minimizing adverse effects, </strong>see <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/\">Scenario: Topical treatment</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Coulson, 1996</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Brayfield, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>]</p><!-- end field edce00d9-1cce-4c42-a2f1-c6739e81305d --><!-- end item 009484c5-7974-45d4-9f8d-ffda6f629d46 -->","subChapters":[]},{"id":"b36219d4-2581-52c3-8b07-cec81c624231","slug":"usage-instructions","fullItemName":"Usage instructions","depth":3,"htmlHeader":"<!-- begin field 9fd86238-213a-473d-93c9-995c0d35f389 --><h3>What should I advise on how to use a topical corticosteroid?</h3><!-- end field 9fd86238-213a-473d-93c9-995c0d35f389 -->","summary":"","htmlStringContent":"<!-- begin item b5d914dd-0608-4e1e-a4a8-2a921af26789 --><!-- begin field e6ee6e82-6a89-4afd-a818-375757b54765 --><ul><li><strong>Advise the person on how to apply the topical steroid. They should:</strong><ul><li>Apply the product sparingly to all the affected areas. Most products will be supplied with an information leaflet which will specify the number of finger-tip units (FTUs) needed to treat specific body areas.<ul><li>One FTU is equivalent to about 500 mg and is sufficient to treat a skin area about twice that of the flat of the hand with the fingers together. The approximate quantity that should be applied for each area of the body is listed in Table 2.</li></ul></li><li>Ideally use their emollient first, then wait several minutes (about 15–30 minutes) before applying the topical corticosteroid (only after the emollient has been fully absorbed).<ul><li>The National Institute for Health and Care Excellence (NICE) states that 'a short interval (several minutes) should be left between application of a topical corticosteroid and an emollient, where practicable' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">National Collaborating Centre for Women's and Children's Health, 2007</a>].</li><li>Some experts advise that there should be a time interval of at least 30 minutes between the application of a topical corticosteroid and an emollient [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Moncrieff et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>]; however, this may not always be practical.</li></ul></li><li>Apply their topical corticosteroid at a time of the day most convenient to them, for example just after the person has washed and applied emollients and/or at night before sleep (this is particularly suitable if they are using ointments).</li></ul></li><li><strong>For flares of eczema, advise the person to:</strong><ul><li>Apply the topical corticosteroid no more than twice a day. For many people, once daily application will be sufficient, but this can be increased if there is an inadequate response.</li><li>Continue treatment for 48 hours after the eczema has cleared (if it has not improved after 2 weeks, the person should return for further advice).</li></ul></li><li><strong>For maintenance of chronic eczema, advise the person:</strong><ul><li>To apply the topical corticosteroid once daily (on treatment days).</li><li>That the treatment should be continued indefinitely, although an occasional drug holiday is advisable when step down treatment is being used.</li></ul></li></ul><p><strong>Table 2. </strong>Quantity of topical corticosteroid to apply for one application.</p><table><thead><tr><th colspan=\"1\">Body area</th><th colspan=\"1\">Number of finger-tip units* (FTUs) for adults and children</th></tr></thead><tbody><tr><td colspan=\"1\" rowspan=\"2\">Face and neck</td><td colspan=\"1\">Adult: 2.5 </td></tr><tr><td colspan=\"1\">Children: 6–10 years: 2; 3–5 years: 1.5; 1–2 years: 1.5; 3–12 months: 1</td></tr><tr><td colspan=\"1\" rowspan=\"2\">Arm and hand</td><td colspan=\"1\">Adult: 4 </td></tr><tr><td colspan=\"1\">Children: 6–10 years: 2.5; 3–5 years: 2; 1–2 years: 1.5; 3–12 months: 1</td></tr><tr><td colspan=\"1\" rowspan=\"2\">Leg and foot</td><td colspan=\"1\">Adult: 8 </td></tr><tr><td colspan=\"1\">Children: 6–10 years: 4.5;3–5 years: 3; 1–2 years: 2; 3–12 months: 1.5</td></tr><tr><td colspan=\"1\" rowspan=\"2\">Trunk (front)</td><td colspan=\"1\">Adult: 7 </td></tr><tr><td colspan=\"1\">Children: 6–10 years: 3.5; 3–5 years: 3; 1–2 years: 2; 3–12 months: 1</td></tr><tr><td colspan=\"1\" rowspan=\"2\">Trunk (back) including buttocks</td><td colspan=\"1\">Adult: 7 </td></tr><tr><td colspan=\"1\">Children: 6–10 years: 5; 3–5 years: 3.5; 1–2 years: 3; 3–12 months: 1.5</td></tr><tr><td colspan=\"2\">* One adult fingertip unit (FTU) is the amount of ointment or cream expressed from a tube with a standard 5mm diameter nozzle, applied from the distal crease to the tip of the index finger.</td></tr><tr><td colspan=\"2\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">MeReC, 1999</a>]</td></tr></tbody></table><!-- end field e6ee6e82-6a89-4afd-a818-375757b54765 --><!-- end item b5d914dd-0608-4e1e-a4a8-2a921af26789 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}